| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
It acts as a potent agonist at the thromboxane A2 (TP) receptor in vivo, inducing vasoconstriction and platelet aggregation. It also enhances receptor-activated NFkappaB ligand (RANKL)-dependent osteoclastic potential of bone marrow hematopoietic precursors via the cAMP pathway. It is also a bronchoconstrictor.
|
|---|---|
| ln Vitro |
8-iso PGE2 is a potent renal vasoconstrictor in the rat. It inhibits U-46619 or I-BOP-induced platelet aggregation with IC50 values of 0.5 and 5 uM, respectively. It has also been studied for its effects on intraocular pressure (IOP) in monkeys, where it significantly reduced IOP for up to 4 hours post-administration.
|
| ln Vivo |
When infused into the renal artery of the rat at a concentration of 4 ug/kg/min, 8-iso PGE2 decreases the GFR and renal plasma flow by 80% without affecting blood pressure. It is increasingly recognized as a non-invasive biomarker for oxidative stress monitoring in conditions like heart failure. It also shows potential in bone metabolism studies, enhancing osteoclast differentiation.
|
| Enzyme Assay |
For a cell-free receptor binding assay, membranes prepared from cells expressing the human TP receptor are incubated with [3H]-SQ 29,548 (a TP antagonist) and increasing concentrations of 8-iso PGE2 (1 nM to 10 uM) in binding buffer (50 mM Tris-HCl, pH 7.4, containing 10 mM MgCl2 and 1 mM EDTA). The mixture is incubated at 25degC for 60 min. Bound radioligand is separated by filtration, and the radioactivity is counted. The Ki value for 8-iso PGE2 at the TP receptor is calculated from competition curves.
|
| Cell Assay |
For in vitro cell assays, bone marrow hematopoietic precursors are isolated from mouse femurs. Cells are seeded in alpha-MEM medium containing 10% FBS and are treated with 8-iso PGE2 (0.01-1 uM) in the presence of RANKL and M-CSF to induce osteoclast differentiation. After 5-7 days, cells are fixed and stained for TRAP (tartrate-resistant acid phosphatase) activity. The number of TRAP-positive multinucleated cells (osteoclasts) is counted to assess the enhancement of osteoclastic potential via the cAMP pathway.
|
| Animal Protocol |
For in vivo studies to measure oxidative stress, a heart failure (HF) animal model (e.g., rats post-myocardial infarction) is used. Blood or saliva samples are collected. The levels of 8-iso PGE2 in plasma or saliva are measured using a commercially available enzyme immunoassay (EIA) or ELISA kit. Elevated levels of 8-iso PGE2 indicate increased systemic oxidative stress. For IOP studies, 0.1% 8-iso PGE2 is topically applied to the eyes of monkeys and IOP measured at intervals.
|
| ADME/Pharmacokinetics |
8-iso PGE2 (MW: 352.5) has moderate stability. It is typically stored as a powder at -20degC to prevent degradation. It is soluble in organic solvents like DMSO and ethanol, as well as in PBS. In biological matrices (plasma, urine), it has a limited stability due to potential metabolism, so samples are often stored at -80degC. Its formation ex vivo is a common artifact if samples are not properly handled.
|
| Toxicity/Toxicokinetics |
As a naturally occurring isoprostane, it is not considered acutely toxic. However, its biological activity is potent (e.g., vasoconstriction and platelet aggregation). Prolonged high levels are associated with pathology related to oxidative stress. For laboratory use, standard precautions should be taken. It is not intended for human use.
|
| References |
|
| Additional Infomation |
8-Table-Prostaglandin E2 is a prostaglandin compound with an 8-position stereochemical configuration opposite to that of prostaglandin E2. It is a rat metabolite, bronchodilator, vasoconstrictor, and human metabolite. It is a cyclic ketone, secondary alcohol, prostaglandin compound, and diol. Its function is related to that of prostaglandin E2.
8-iso PGE2 is established as a key biomarker for oxidative stress and lipid peroxidation in numerous human diseases. It is used as a reference standard in analytical chemistry and as a pharmacological tool to study TP receptor signaling. It is not a drug but a research compound for investigating the pathophysiology of oxidative stress-related diseases. |
| Molecular Formula |
C20H32O5
|
|---|---|
| Molecular Weight |
352.46508
|
| Exact Mass |
352.224
|
| CAS # |
27415-25-4
|
| PubChem CID |
5283213
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
530.1±50.0 °C at 760 mmHg
|
| Flash Point |
288.5±26.6 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.561
|
| LogP |
1.88
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
25
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@H]1C/C=C\CCCC(=O)O)O)O
|
| InChi Key |
XEYBRNLFEZDVAW-CLQOMRTCSA-N
|
| InChi Code |
InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16-,17+,19+/m0/s1
|
| Chemical Name |
(Z)-7-[(1S,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8371 mL | 14.1856 mL | 28.3712 mL | |
| 5 mM | 0.5674 mL | 2.8371 mL | 5.6742 mL | |
| 10 mM | 0.2837 mL | 1.4186 mL | 2.8371 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
